Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study
Pharmaceutical Technology
Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs.
pharminent
April 16, 2026 (Last updated: April 16, 2026)
Pharmaceutical Technology
Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs.